Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

By Sunpaweravong Patrapim   Magree Lyn   Rabinovitch Rachel   Bunn Paul   Kelly Karen  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 213-221

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis

By Garcia Agustin   Iqbal Syma   Quinn David   Edwards Susan   Lenz Heinz   Weber Jeff  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 79-83

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer

By Montero Alberto   Booser Daniel   Esparza-Guerra Laura   Murray James   Rosales Marguerite   Hortobagyi Gabriel   Valero Vicente  

Drugs in R&D, Vol. 6, Iss. 5, 2005-01 ,pp. : 299-305

Adis International

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite